Literature DB >> 2013510

In-vitro susceptibility of cefoperazone-susceptible and -resistant gram-negative rods to cefoperazone plus sulbactam, other beta-lactams, aminoglycosides and quinolone.

P H Chandrasekar1, J A Sluchak.   

Abstract

We compared the in-vitro activity of cefoperazone-sulbactam (2:1), other beta-lactams, amino-glycosides and ciprofloxacin against cefoperazone-susceptible and -resistant nosocomial gram-negative bacilli. Resistant isolates including Pseudomonas aeruginosa were susceptible to cefoperazone-sulbactam; the susceptible isolates had modestly increased susceptibility to the combination. Sulbactam, by itself, was poorly active. Among others tested, ciprofloxacin and imipenem were the most active. No inoculum effect was seen with cefoperazone-sulbactam and this drug combination had a prolonged post-antibiotic effect. Cefoperazone-sulbactam is an attractive candidate for evaluation in the treatment of nosocomial infections due to aerobic gram-negative bacilli.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013510     DOI: 10.1007/bf01643761

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  12 in total

1.  In vitro activity of sulbactam in combination with various beta-lactam antibiotics.

Authors:  J Klastersky; P Van der Auwera
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Jul-Aug       Impact factor: 2.803

2.  Synergistic activity of cefoperazone in combination with beta-lactamase inhibitors.

Authors:  K P Fu; H C Neu
Journal:  J Antimicrob Chemother       Date:  1981-03       Impact factor: 5.790

3.  Variation in the potentiation of beta-lactam antibiotic activity by clavulanic acid and sulbactam against multiply antibiotic-resistant bacteria.

Authors:  K E Aldridge; C V Sanders; R L Marier
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

4.  In vitro assessment of sulbactam plus cefoperazone in the treatment of bacteria isolated from cancer patients.

Authors:  G P Bodey; P Miller; D H Ho
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Jul-Aug       Impact factor: 2.803

5.  Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.

Authors:  D P Reitberg; D A Marble; R W Schultz; T J Whall; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

Review 6.  Concept of empiric therapy with antibiotic combinations. Indications and limits.

Authors:  J Klastersky
Journal:  Am J Med       Date:  1986-05-30       Impact factor: 4.965

7.  Activity of beta-lactamase inhibitors in combination with new beta-lactam antibiotics against resistant gram-negative organisms.

Authors:  R Bolivar; S S Weaver; G P Bodey
Journal:  Diagn Microbiol Infect Dis       Date:  1984-06       Impact factor: 2.803

Review 8.  Bacterial resistance to fluoroquinolones.

Authors:  H C Neu
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

9.  In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies.

Authors:  R N Jones; H W Wilson; C Thornsberry; A L Barry
Journal:  Diagn Microbiol Infect Dis       Date:  1985-11       Impact factor: 2.803

10.  Efficacy of sulbactam/cefoperazone for the treatment of infections in patients with hematologic diseases.

Authors:  A Horiuchi; H Hasegawa; T Kageyama; T Yonezawa; T Kitani; T Masaoka; K Yasunaga; H Kawagoe; K Nagai
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Jul-Aug       Impact factor: 2.803

View more
  2 in total

1.  Therapy with cefoperazone plus sulbactam against disseminated infection due to cefoperazone-resistant Pseudomonas aeruginosa and Escherichia coli in granulocytopenic mice.

Authors:  P H Chandrasekar; J A Sluchak; J A Kruse
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

Review 2.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.